

Certified English Translation (*Original Chinese Charter stamped and approved by the supporting entity*)

Center Charter
Nanjing Engineering Research Center for Anti-AMR
Nanomaterials
International Submission Version (Revised March
2026)

Chapter 1 General Provisions

Article 1 Nature and Positioning

The Center is a government-recognized research platform dedicated to public health and scientific research.

It operates as an independent research and collaboration platform and is not part of any single commercial entity's business operations.

The Center operates in alignment with international public health principles.

Article 2 Non-commercial Principle

The Center serves public health and scientific objectives.

In international collaboration and platform participation, it does not engage in commercial promotion or product-oriented activities.

Article 3 Support Relationship

NMS Technologies Co., Ltd. provides administrative, technical, and infrastructure support to the Center.

Such support does not constitute ownership or control.

The supporting entity does not influence the Center's research direction, academic decision-making, or international participation.

Article 4 Multi-stakeholder Collaboration

The Center collaborates with universities, healthcare institutions, research organizations, and public health bodies to promote multi-stakeholder cooperation and innovation.

Article 5 One Health Approach

The Center supports the One Health approach, integrating human, animal, and environmental health perspectives.

Article 6 Governance and Transparency

The Center maintains a transparent and accountable governance structure, ensuring alignment with scientific integrity and public health objectives.

The Center operates in a transparent and accountable manner in international collaborations.

Chapter 2 Governance Structure

Article 7 Leadership

The Center implements a Director Responsibility System.

The Director is responsible for overall administration and operations.

Article 8 Research and Development

The R&D Director is responsible for research direction and major technical decisions.

Article 9 Academic Committee

The Center has established an Academic Committee composed of experts to guide scientific research and academic activities.

Article 10 Compliance and Standards

All clinical research follows Good Clinical Practice (GCP) standards and is registered in recognized clinical trial registries.

Relevant production systems follow applicable quality management standards, including ISO 13485 where applicable.

Article 11 Collaboration Initiatives

The Center promotes collaborative initiatives in antimicrobial resistance (AMR) and One Health-related fields.

Chapter 3 Legal Status and Authorization

Article 12 Charter Status

This Charter has been filed and confirmed by the supporting entity.

Article 13 Independence in Participation

The Center operates as an independent research and collaboration platform and may participate in international initiatives in accordance with its institutional functions.

The supporting entity provides necessary support but does not exercise control over the Center's international participation or decision-making.

Chapter 4 Supplementary Provisions

Article 14 Effective Date

This Charter takes effect upon issuance.

NMS Technologies Co., Ltd. (Supporting Entity)

Legal Representative (Signature / Seal): _____

Date: March 2026

南京市抗耐药纳米材料工程技术研究中心

中心章程

(2026年3月修订)

第一章 总则

第一条 性质与定位

本中心为经政府认定的科研平台，致力于公共卫生与科学研究。
本中心作为独立运行的科研与协作平台存在，不属于任何单一商业主体的业务体系。
本中心的运行遵循国际公共卫生原则。

第二条 非商业原则

本中心以公共卫生和科学研究为目标。
在国际合作及平台参与过程中，不开展商业推广或以产品为导向的活动。

第三条 支持关系

南京神奇科技开发有限公司为本中心提供行政、技术及基础设施支持。
上述支持不构成所有权或控制关系。
依托单位不影响本中心的科研方向、学术决策及国际合作参与。

第四条 多方协作

本中心与高校、医疗机构、科研组织及公共卫生机构开展合作，推动多利益相关方协作与创新。

第五条 同一健康理念

本中心支持“同一健康（One Health）”理念，促进人类、动物及环境健康的协同发展。

第六条 治理与透明性



本中心建立透明且负责任的治理结构，确保符合科学诚信与公共卫生目标。在国际合作中，本中心以透明和可问责的方式运行。

第二章 治理结构

第七条 领导机制

本中心实行主任负责制。
主任负责整体管理与运营。

第八条 科研管理

科研负责人负责研究方向及重大技术决策。

第九条 学术委员会

本中心设立由专家组成的学术委员会，指导科研工作与学术活动。

第十条 合规与标准

所有临床研究遵循《药物临床试验质量管理规范（GCP）》并在认可的临床试验注册平台登记。
相关生产体系遵循适用的质量管理标准，包括 ISO 13485（如适用）。

第十一条 协同项目

本中心推动抗微生物耐药性（AMR）及“同一健康”相关领域的协同项目。

第三章 法律地位与参与机制

第十二条 章程效力

本章程经依托单位备案确认后生效。

第十三条 独立参与机制



本中心作为独立运行的科研与协作平台,可根据自身职能参与国际合作与相关平台。
依托单位提供必要支持,但不对本中心的国际参与及决策进行控制。

第四章 附 则

第十四条 生效时间

本章程自发布之日起生效。

南京神奇科技开发有限公司（依托单位）

公司公章:



日期: 2026年3月

